Loading clinical trials...
Loading clinical trials...
Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function
Conditions
Interventions
LY3473329
Locations
4
United States
Velocity Clinical Research, New Smyrna Beach
Edgewater, Florida, United States
Advanced Pharma CR, LLC
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, United States
Start Date
March 17, 2023
Primary Completion Date
September 6, 2024
Completion Date
September 6, 2024
Last Updated
October 28, 2024
NCT07262333
NCT01524276
NCT07203131
NCT02769975
NCT06660277
NCT06314503
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions